• AIM ImmunoTech posted a net loss of USD 3.79 million for the quarter ended June 30, 2026, widening 35.6% year over year.
• Operating loss widened 32.8% to USD 3.51 million as total costs and expenses rose 32.5% to USD 3.54 million.
• Revenue edged up 4% to USD 26,000 while research and development expense fell 49.8% to USD 589,000.
• General and administrative expense climbed 98% to USD 2.95 million, attributed to offering-related costs tied to multiple equity transactions.
• Cash and cash equivalents rose to USD 9.9 million at June 30, 2026, up 231.7% from Dec. 31, 2025.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-036609), on August 07, 2026, and is solely responsible for the information contained therein.